生命科学资讯

ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success

‘Market’s thinking is backwards’: FDA’s 1-trial approval plan would boost R&D spend, Jefferies says

FDA panel votes against J&J's novel shunt implant for heart failure

Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M

Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data

'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out

How AI and real-world evidence are powering smarter decisions across the drug and device development lifecycle

A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine

Chutes & Ladders—Yet another CDER leadership shake-up

Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA

Cancer blood test developer Freenome to go public in $330M SPAC deal

Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&D hub's capability

FDA slaps hold on Denali's plans for phase 1 rare disease trial

GE HealthCare, Mayo Clinic launch digital twin project for personalizing radiation cancer therapy

Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche’s Flatiron

After dodging Biosecure threat, WuXi AppTec faces new security scrutiny from Pentagon: Bloomberg

Crescent waxes pipeline with $80M Kelun deal, bagging ADC to pair with PD-1xVEGF bispecific

Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision

After more than 20 years, Medtronic claims deep brain stimulation approval for dystonia

A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes